ScoreWhy is Astrazeneca Pharma India Ltd ?
1
Poor long term growth as Operating profit has grown by an annual rate 15.14% of over the last 5 years
2
Flat results in Mar 26
- PBT LESS OI(Q) At Rs 53.27 cr has Fallen at -12.6% (vs previous 4Q average)
- PAT(Q) At Rs 45.71 cr has Fallen at -12.2% (vs previous 4Q average)
3
With ROE of 24, it has a Very Expensive valuation with a 25.8 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -19.21%, its profits have fallen by -5.3%
4
Underperformed the market in the last 1 year
- Even though the market (BSE500) generated negative returns of -2.24% in the last 1 year, its fall in the stock was much higher with a return of -19.21%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Astrazeneca Phar for you?
Medium Risk, Low Return
Absolute
Risk Adjusted
Volatility
Astrazeneca Phar
-19.08%
-0.78
24.31%
Sensex
-7.55%
-0.58
13.06%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
22.84%
EBIT Growth (5y)
15.14%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.46
Sales to Capital Employed (avg)
1.88
Tax Ratio
25.65%
Dividend Payout Ratio
69.12%
Pledged Shares
0
Institutional Holding
8.58%
ROCE (avg)
97.56%
ROE (avg)
21.62%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
108
Industry P/E
27
Price to Book Value
25.77
EV to EBIT
86.64
EV to EBITDA
77.19
EV to Capital Employed
46.62
EV to Sales
8.89
PEG Ratio
NA
Dividend Yield
0.39%
ROCE (Latest)
63.10%
ROE (Latest)
23.97%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend4What is working for the Company
NET SALES(9M)
At Rs 1,749.27 cr has Grown at 31.65%
-6What is not working for the Company
PBT LESS OI(Q)
At Rs 53.27 cr has Fallen at -12.6% (vs previous 4Q average
PAT(Q)
At Rs 45.71 cr has Fallen at -12.2% (vs previous 4Q average
Loading Valuation Snapshot...
Here's what is working for Astrazeneca Phar
Net Sales - Latest six months
At Rs 1,190.18 cr has Grown at 29.26%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Here's what is not working for Astrazeneca Phar
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 53.27 cr has Fallen at -12.6% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 60.92 CrMOJO Watch
Near term PBT trend is very negative
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 45.71 cr has Fallen at -12.2% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 52.07 CrMOJO Watch
Near term PAT trend is very negative
PAT (Rs Cr)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
